FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Wolf Jeffrey Alan					2. Issuer Name and Ticker or Trading Symbol Synthetic Biologics, Inc. [ SYN ]								tionship of all applicat Director		ng Pers	on(s) to Iss		
(Last)	,	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/17/2014								Officer (g below)	ive title		Other (s	specify	
C/O SYNTHETIC BIOLOGICS, INC., 155 GIBBS STREET, SUITE 412					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	lividual or Joint/Group Filing (Check Applicable				.	
(Street)	LLE 1	MD	20850									X	Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City)	(	State)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				. Transaction Date Month/Day		Execution any	2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a		5. Amount of Securities Beneficially Following Re	Owned or In		Direct (D) rect (I) 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	Transaction (Instr. 3 and	1.7			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Security or Exercise (Month/Day/Year) Execution Date, if Conversion (Month/Day/Year) Execution Date, if Conversion (Month/Day/Year) Execution Date, if Conversion (Month/Day/Year) Execution Date, if Conversion (Month/Day/Year) Execution (Month/Day/Year)			4. Transac Code (Ir 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		Reporte Transac (Instr. 4	tion(s)			
Stock Options (Right to Buy)	\$2.52	04/17/2014		A		105,000 <sup>(1)</sup>		04/17/20	4 0	4/16/2024	Common Stock	105,000	\$0	105,0	000	D		

## Explanation of Responses:

1. These options, representing an up-front grant for his services as a director for the three years next following, will vest annually over a three year period in three equal installments, with one-third vesting on the date of grant and one-third vesting on each of April 17, 2015 and April 17, 2016, respectively.

> /s/ Jeffrey A. Wolf 04/21/2014

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $\star$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.